Tilray Brands Inc TLRY

Tilray Brands not benefited in any way whatsoever

[Keeler]

by the news release Ventura posted below.
As I've posted several times - I hold 5 US MSOs, including Cannabist, Cresco and Curaleaf - interested in what will happen next week.

Medmen - the soon to be bankrupt company that Tilray purchased $200 million worth of debentures - will NOT receive a licence, as I posted two months ago when this news came out - they simply don't have the cash for the additional licencing fee.

Medmen - after repeated delays, financial mis-statements, irregularities and CFO resignations has delayed releas of its financial statements several times and are current in a cease trade order for management. 

The latest extension ends next week - Dec 13 - it seems likely that the financials will be a final disaster.

Tikray HAD to have US legalization zation in order to acquire Medmen before cpiration of the debentures/warrants. They will come due - Medmen will not be able to repay Tilray and have no choice but to declare bankruptcy.
Tilray will lose the $200 million (USD) that Simon wasted on yet another poor business decision. The decision wasn't bad because of the concept - it was bad because Medmen was in trouble when Tilray acquired the debt - just like Hexo was when Simon paid $200 million for THAT bankrupt company.

Who will buy Medmen NY licences? Probably Cresco or Curaleaf - or they'll simply be put up by the state as 'available' with a new application process.

Ventura stated numerous times that Medmen was a great company - and that he personally owned 60,000 shares at .02 cents. Easiest $1,200 he ever list.

 

Post by Ventura2020on Dec 08, 2023 3:23pm

77 Views 

Post# 35775506

Tilray Brands - New York, New York

The R.O.'s will have to reserve 50% of their shelf space for brands they don't own.

New York marijuana regulators on Friday gave the formal thumbs up to six of the state’s 10 licensed medical marijuana companies – most of which are large multistate operators – to begin adult-use cannabis sales on Dec. 29, precisely one year after recreational sales were launched in the Empire State.

The half dozen that got the green light from the state Cannabis Control Board include:

• Columbia Care NY LLC (NEO: CCHW) (OTCQX: CCHWF)
• Curaleaf NY LLC (CSE: CURA) (OTCQX: CURLF)
• Etain LLC, which is owned by Riv Capital (CSE: RIV) (OTC: CNPOF)
• NYCANNA LLC, which is owned by Acreage Holdings Inc. (CSE: ACRG.A.U) (OTCQX: ACRHF)
• PharmaCann of New York LLC
• Valley Agriceuticals LLC, which is owned by Cresco Labs (CSE: CL) (OTCQX: CRLBF)

Ultimately those six companies will be permitted to set up co-located recreational sales at up to three of their existing medical dispensaries, but for the time being, each was only approved for a single shop that can open by the end of the month.

Four other New York medical marijuana companies weren’t mentioned during the CCB meeting, but technically they are eligible to apply for transition into the recreational market, including:

• Citiva Medical LLC, which is owned by iAnthus Capital Holdings Inc. (CSE: IAN) (OTCQB: ITHUF)
• Fiorello Pharmaceuticals Inc., which is owned by Green Thumb Industries (CSE: GTII) (OTC: GTBIF)
• MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF)
• Vireo Health International, which does business as Goodness Growth Holdings (CSE: GDNS) (OTCQX: GDNSF)

The CCB also approved new medical-only dispensary locations for both Citiva and Fiorello at Friday’s meeting, giving the former permission to open a dispensary in Ithaca and the latter for one on Long Island.

“The registered organizations being considered today have submitted the required materials to transition, including a community impact plan, medical patient prioritization plan, and an energy and environmental plan,” Damian Fagon, chief equity officer at the Office of Cannabis Management, told the board Friday.

“We are excited to have ‘registered organizations‘ enter the market, while continuing to prioritize and expand offerings to medical patients,” Fagon said, adding that the OCM recommended the allowance of all six so-called “R.O.’s.”
https://www.greenmarketreport.com/new-york-regulators-greenlight-rec-market-entrance-of-six-medical-cannabis-behemoths/